Eurofins Scientific ERF.PA
Eurofins Scientific is a Luxembourg-based global leader in laboratory testing services, offering a broad portfolio of tests and assays for the pharmaceutical, food, environmental, and consumer products industries. Eurofins shows earnings growth of 28.4% with a forward P/E of 16.76 and a PEG of 0.93, suggesting the market has not yet fully priced in its potential. Financial health is adequate (ND/EBITDA 2.51) and the €414 million buyback reinforces confidence, although cash conversion (22.09%) is a weak point to watch.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Eurofins Scientific is a Luxembourg-based global leader in laboratory testing services, offering a broad portfolio of tests and assays for the pharmaceutical, food, environmental, and consumer products industries. Eurofins shows earnings growth of 28.4% with a forward P/E of 16.76 and a PEG of 0.93, suggesting the market has not yet fully priced in its potential. Financial health is adequate (ND/EBITDA 2.51) and the €414 million buyback reinforces confidence, although cash conversion (22.09%) is a weak point to watch.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.8 |
| Quality / Moat | 4.7 |
| Valuation | 5.5 |
| Growth | 6.6 |
| Dividend | 5.0 |
| Momentum | 5.8 |
| Risk & Context | 7.0 |
OVERALL SCORE: 5.7/10
Context and risks
Domiciled in Luxembourg with moderate governance risk. The laboratory business has no direct exposure to rates, energy, or geopolitics that is material to its results.
News considered in the analysis
- Eurofins Scientific (ENXTPA:ERF) Reports Insider Sales, Is The Stock Fairly Valued? — Ventas de insiders pueden indicar falta de confianza, pero son de magnitud limitada y no cambian el panorama fundamental.
- Is Eurofins Scientific (ENXTPA:ERF) Fairly Valued On Its €414 Million Share Buyback? — Un programa de recompra de 414 millones de euros es una señal positiva de confianza de la dirección y apoyo al precio de la acción.
- Eurofins Scientific (ENXTPA:ERF) Stock Looks Reasonable Despite A Wide Fair Value Gap — Artículo de análisis de valoración sin información nueva o concreta que afecte a los fundamentales.
- Eurofins Scientific SE (ERFSF) (H1 2026) Earnings Call Highlights: Strong EPS Growth and Margin ... — Resultados del primer semestre con fuerte crecimiento del BPA y mejora de márgenes, una señal claramente positiva para el negocio.
- Assessing Eurofins Scientific (ENXTPA:ERF) Valuation After Recent Share Price Momentum — Análisis de valoración post-movimiento del precio, sin información fundamental nueva.
Verdict: Hold or buy on dips; earnings growth and an attractive forward valuation offer a good risk-reward balance.
Main risk: Weak cash conversion (22.09%) and a high gross margin (23.13%) suggest competitive pressure or operational inefficiencies that could limit the ability to sustain earnings growth in the long term.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →